Leukemia, Myeloid Chronic
29
1
1
16
Key Insights
Highlights
Success Rate
64% trial completion
Published Results
11 trials with published results (38%)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
31.0%
9 terminated out of 29 trials
64.0%
-22.5% vs benchmark
10%
3 trials in Phase 3/4
69%
11 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (29)
Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Who Have Been Previously Treated With Imatinib and Have Not Achieved Deep Molecular Response.
Study of HQP1351 in Subjects With Refractory CML and Ph+ ALL
The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)
Sirolimus/Tacrolimus Versus Tacrolimus/Methotrexate for Preventing Graft-Versus-Host Disease (GVHD) (BMT CTN 0402)
Efficacy and Safety of LBH589B in Adult Patients With Refractory Chronic Myeloid Leukemia in Accelerated or Blast Phase
Stem Cell Transplant for Hematological Malignancy
Transplantation of Umbilical Cord Blood Following Chemotherapy for Blood Cancers
Post Transplant Donor Lymphocyte Infusion
Randomized Double Cord Blood Transplant Study
Donor Lymphocyte Infusion (DLI) for Relapsed (Post Transplant) Leukemia
Safety Assessment of Two Schedules of Intravenous Infusions of SNS-595 for the Treatment of Hematologic Malignancies
Efficacy and Safety of Oral AMN107 in Adults With Chronic Myelogenous Leukemia Resistant and/or Intolerant to Imatinib Mesylate Therapy
High-Dose Gleevec Alone or in Combination With Peg-Intron and GM-CSF in Early Phase Chronic Myelogenous Leukemia (CML)
Study of Ipilimumab and Dasatinib Combination Therapy in Patients With Chronic or Accelerated Chronic Myeloid Leukemia
An Open-Label, Multicenter, Expanded Access Study of Oral AMN 107 in Adult Patients With Imatinib (Glivec®/Gleevec®_ - Resistant or Intolerant Chronic Myeloid Leukemia in Blast Crisis, Accelerated Phase or Chronic Phase
Hematopoietic Stem Cell Transplantation (HSCT) Using CD34 Selected Mismatched Related Donor and One Umbilical Cord Unit
Study of Farnesyl Protein Transferase Inhibitor (FPTI) in Patients With Leukemia (Study P00701)
Study of Dasatinib in Patients With Chronic Phase Chronic Myeloid Leukemia and a Suboptimal Response to Imatinib
Study of Parathyroid Hormone Following Sequential Cord Blood Transplantation From an Unrelated Donor
Sibling and Unrelated Donor Hematopoietic Cell Transplant in Hematologic Malignancies